Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$136.52 USD

136.52
7,975,199

+7.51 (5.82%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $137.20 +0.68 (0.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top

by Zacks Equity Research

Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.

    Zacks Equity Research

    Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2

    by Zacks Equity Research

    Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.

      Zacks Equity Research

      Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View

      by Zacks Equity Research

      Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.

        Zacks Equity Research

        ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track

        by Zacks Equity Research

        ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.

          Zacks Equity Research

          DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

          by Zacks Equity Research

          DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.

            Zacks Equity Research

            VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2

            by Zacks Equity Research

            VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.

              Zacks Equity Research

              IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up

              by Zacks Equity Research

              IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

                Zacks Equity Research

                Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues

                by Zacks Equity Research

                Hill-Rom Holdings (HRC) rides high on international growth and product innovation.

                  Zacks Equity Research

                  Company News For July 31, 2017

                  by Zacks Equity Research

                  Companies in the news are: EXPE,MRK,ALGN,MAT

                    Zacks Equity Research

                    NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View

                    by Zacks Equity Research

                    NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.

                      Zacks Equity Research

                      Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2

                      by Zacks Equity Research

                      Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.

                        Zacks Equity Research

                        AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?

                        by Zacks Equity Research

                        AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.

                          Zacks Equity Research

                          Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1

                          by Zacks Equity Research

                          Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.

                            Zacks Equity Research

                            GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates

                            by Zacks Equity Research

                            Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).

                              Zacks Equity Research

                              Align Technology (ALGN) Beats on Q2 Earnings and Revenues

                              by Zacks Equity Research

                              Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.

                                Zacks Equity Research

                                QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

                                by Zacks Equity Research

                                QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

                                  Zacks Equity Research

                                  Merit Medical Systems (MMSI) Worth a Look: Stock Gains 7.7%

                                  by Zacks Equity Research

                                  Merit Medical Systems, Inc. (MMSI) shares rose almost 8% in the last trading session.

                                    Zacks Equity Research

                                    McKesson (MCK) Misses Earnings Estimates in Q1, Raises View

                                    by Zacks Equity Research

                                    McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.

                                      Zacks Equity Research

                                      Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss

                                      by Zacks Equity Research

                                      Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.

                                        Zacks Equity Research

                                        CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2

                                        by Zacks Equity Research

                                        CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.

                                          Zacks Equity Research

                                          LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up

                                          by Zacks Equity Research

                                          LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.

                                            Zacks Equity Research

                                            Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

                                            by Zacks Equity Research

                                            The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

                                              Zacks Equity Research

                                              Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised

                                              by Zacks Equity Research

                                              Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.

                                                Zacks Equity Research

                                                Should You Buy Align Technology (ALGN) Ahead of Earnings?

                                                by Zacks Equity Research

                                                Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

                                                  Zacks Equity Research

                                                  Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up

                                                  by Zacks Equity Research

                                                  Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.